The Hidden Cost of Disconnected Clinical Trials

Florence’s new report, The Hidden Cost of Disconnected Clinical Trials, examines why study timelines keep lengthening despite a decade of heavy investment in eTMF, CTMS, eConsent, ePRO, and remote monitoring.

This report goes beyond the site burden conversation. It puts a number on what disconnected workflows cost sponsors and CROs, and defines what a connected study actually requires.

Inside the report, you’ll uncover:

• The Visibility Gap
  Why study startup timelines have grown 30% to 45% since 2015 despite unprecedented technology investment, and why nearly half of research sites now accept fewer studies because of sponsor technology burden.
• The True Cost of Disconnected Study Workflows
  How monitoring overhead, document cycle time, and TMF rework accumulate into thousands of hours across a portfolio, and why a single week of Phase III delay now carries roughly $3.9M in direct study costs.
• Study Startup: Where Fragmentation Becomes Visible
  Why activation stalls in the handoffs between budgets, contracts, and regulatory review, with more than a quarter of sites spending eight weeks or longer on contract negotiation alone.
• Connectivity as a Compliance Requirement
  What ICH E6(R3) means for oversight of systems sponsors do not own, plus a five-question inspection readiness test to run against your own program.
• Five Principles for Building a Connected Clinical Study
  The operating model for connecting the technology you already use: adapt to the site, standardize the operational view, reuse operational knowledge, build in real-time visibility, and design for the entire study ecosystem.

Read the report on what disconnected trials really cost